Predicting hospital readmissions in patients receiving novel-dose Sacubitril/Valsartan therapy: A competing-risk, causal mediation analysis

• DOI: 10.1101/2023.02.08.23285680
• Publication Date: 2023-02-10T18:32:30Z
• Authors: Changchun Hou; Xinxin Hao; Ning Sun; Xiaolin Luo; Luyu Wang; Enpu Yang; Zhichun Gao; Ling Chen; Zebi Wang; Yun Cui; Jing Zhong; Juhao Yang; Xi Liu; Zhexue Qin
• Keywords: Nomogram

Abstract Background The effects of novel-dose Sacubitril/Valsartan (S/V) in patients with heart failure (HF) the real world have not been adequately studied. We examined risk for all-cause re-admission HF taking S/V and possible mediator role left ventricular reverse remodeling (LVRR). Methods Results There were 464 recruited from December 2017 to September 2021 our hospital a median follow-up 660 days (range, 17-1494). Model 1 2 developed based on results univariable competing analysis, least absolute shrinkage selection operator approach, backward stepwise regression multivariable analysis. internal verification (data-splitting method) indicated that had better discrimination, calibration, clinical utility. corresponding nomogram showed aged 75 years above, or lowest-dose (≤50mg twice day), diagnosed tachycardia, valvular disease, chronic obstructive pulmonary diabetes mellitus at highest readmission. In causal mediation LVRR was considered as critical negatively affected difference Conclusions A significant association detected between readmission patients, part mediated by LVRR. web-based could provide individual prediction receiving S/V. different are still needed be explored further future.